Anzeige
Mehr »
Samstag, 06.09.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
212 Leser
Artikel bewerten:
(1)

Bioforum the Data Masters Introduces SUBMIT24: A Free of Charge and Revolutionary CDISC CORE-Based Clinical Data Validation Tool

The new Offering will Include Unparalleled Features and is planned to undergo the CDISC CORE Certification Program

NESS ZIONA, Israel, April 24, 2024 /PRNewswire/ -- Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the launch of SUBMIT24 in its beta version during Q3 2024, a groundbreaking free of charge CDISC CORE-based clinical data validation tool. SUBMIT24 offers a revolutionary approach to data validation, providing users with a downloadable platform.

SUBMIT24 is proud to align with the Clinical Data Interchange Standards Consortium (CDISC), a global nonprofit organization that develops and maintains standards for clinical research. Built on the CDISC standards, SUBMIT24 is designed to streamline the data validation process and enhance efficiency in clinical research. With its user-friendly interface and advanced features, SUBMIT24 empowers users to validate clinical data with ease and accuracy.

"We are excited to introduce SUBMIT24 to the clinical research community," said Amir Malka, CEO. "We believe that clinical data conformance shouldn't come with a price tag and therefor introduce this innovative free of charge tool which represents a significant step forward in data validation."

Key features of SUBMIT24 include:

  • A standalone desktop application that ensures users can validate their clinical data securely in their own environment.
  • Users can add their own custom rules using CDISC CORE syntax.
  • SUBMIT24 offers a range of advanced features to streamline the data validation process.
  • SUBMIT24 is set to undergo the CDISC CORE certification program, further validating its reliability and effectiveness in clinical research.
  • A CFR 21 Part 11 compliant validation package will be publicly available.

"We believe that SUBMIT24 will revolutionize the way clinical data is validated," added Malka. "By providing the industry with access to this powerful tool, we aim to accelerate the pace of clinical research and improve patient outcomes."

"As CDISC CORE rules rapidly evolve, having open and transparent collaboration with our vendor community becomes crucial for the successful adoption of CORE conformance rules in our industry. CDISC plans to create and launch a CORE Rules Certification Program within the next year to certify solutions that are delivering results that match the CORE Rules output and we look forward to having vendors like Bioforum participate in that process." said Peter Van Reusel, Chief Standards Officer, CDISC.

For more information about SUBMIT24, please visit https://www.bioforumgroup.com/services/submit24/

About CDISC

Clinical Data Interchange Standards Consortium (CDISC) is a global non-profit organization that develops and advances data standards of the highest quality to transform incompatible formats, inconsistent methodologies, and diverse perspectives into a robust framework for generating accessible clinical research data. Driven by the belief that the true measure of data is its impact, CDISC convenes a global community of research experts representing a range of experiences and backgrounds to harness the collective power to drive more meaningful clinical research.

About Bioforum

Bioforum The Data Masters is a leading global clinical research organization (CRO) that specializes in biometric services and solutions for the pharmaceutical, biotech and medical device industries. With a team of experienced professionals and state-of-the-art technology, Bioforum provides a range of services including data management, biostatistics, statistical programming and medical writing to help companies bring new drugs and therapies to market faster. To learn more about us and our services, visit www.bioforumgroup.com or find us on LinkedIn at https://il.linkedin.com/company/bioforum-ltd

Contact:

Bioforum Contact
Tali Rahinstein
talir@bioforumgroup.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/bioforum-the-data-masters-introduces-submit24-a-free-of-charge-and-revolutionary-cdisc-core-based-clinical-data-validation-tool-302122771.html

© 2024 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.